The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Pediatric AML Relapse and Hematopoietic Stem Cell Transplantation

Salvage strategies and curative-intent transplantation for relapsed pediatric acute myeloid leukemia

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Pediatric AML Relapse and Hematopoietic Stem Cell Transplantation?

Pediatric AML relapse despite intensive frontline therapy with cytarabine and anthracycline backbone occurs in significant subset.

Salvage chemotherapy options include FLAG-IDA (fludarabine, cytarabine, idarubicin, GCSF), mitoxantrone-based regimens.

Targeted therapies based on molecular features including FLT3 inhibitors, IDH inhibitors, gemtuzumab.

Venetoclax combination with azacitidine or low-dose cytarabine emerging in pediatric population.

Allogeneic HSCT after second complete remission represents curative-intent therapy with substantial mortality.

Symptoms

Relapse presentation includes return of cytopenias, fever, infections, bleeding from bone marrow involvement.
Extramedullary disease including chloroma may herald relapse particularly in monocytic subtypes.
Treatment-related toxicities including cardiotoxicity from prior anthracyclines limit re-treatment options.
Performance status assessment guides treatment intensity and supportive care needs.
Comprehensive molecular reassessment identifies clonal evolution and targeted therapy opportunities.

Risk Factors

High-risk cytogenetics and molecular features at diagnosis predict relapse risk.
Inadequate response to induction therapy increases relapse risk warranting intensification.
Time to relapse from diagnosis affects prognosis with shorter intervals predicting poor outcome.
Extramedullary disease at relapse complicates management requiring radiation considerations.
Prior cumulative anthracycline exposure limits re-treatment with cardiotoxic agents.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • AML relapse warrants urgent evaluation at pediatric oncology center with experience in salvage therapy and transplant.
  • Comprehensive molecular reassessment identifies targeted therapy opportunities and prognostic features.
  • Treatment-related toxicities including infections require immediate evaluation and management.
  • Donor identification process should begin early during salvage to enable timely transplant.
  • Long-term follow-up monitors late effects, secondary malignancies and quality of life issues.

Treatment Methods

01
FLAG-IDA salvage chemotherapy with fludarabine 30 mg/m2 days 1-5, cytarabine 2 g/m2 days 1-5, idarubicin 10 mg/m2 days 1-3.
02
Targeted agent integration based on molecular features including FLT3 inhibitors, IDH inhibitors, gemtuzumab.
03
Allogeneic HSCT with myeloablative conditioning for fit patients in second complete remission.
04
Reduced-intensity conditioning for patients unable to tolerate myeloablative approach.
05
Comprehensive supportive care including infection prophylaxis with antibacterial, antifungal and antiviral agents, transfusion support, growth factor support, treatment of febrile neutropenia, GVHD prevention and management, surveillance for relapse including measurable residual disease assessment, late effects monitoring including cardiotoxicity, secondary malignancies, growth and development effects and psychosocial support for patient and family optimizes outcomes in this challenging clinical scenario.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.